Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 835 Views
-
Last post by NHE
-
- 0 Replies
- 2446 Views
-
Last post by frodo
-
- 0 Replies
- 1119 Views
-
Last post by NHE
-
- 1 Replies
- 1115 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1409 Views
-
Last post by frodo
-
- 0 Replies
- 1654 Views
-
Last post by NHE
-
- 0 Replies
- 2186 Views
-
Last post by vesta
-
- 0 Replies
- 1652 Views
-
Last post by frodo
-
- 0 Replies
- 2278 Views
-
Last post by DIM